Humanized antibody that binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and inhibits
IL-6-mediated signaling through these receptors
t1/2: 11-23 days
Indications:
(1) given via iv or sc for rheumatoid arthritis; (2) given via iv for juvenile idiopathic arthritis (polyarticular or systemic)
Adverse effects: infections; injection/infusion reactions
Tocilizumab